ZA200201403B - Composition comprising a tramadol material and an anticonvulsant drug. - Google Patents

Composition comprising a tramadol material and an anticonvulsant drug. Download PDF

Info

Publication number: ZA200201403B
Authority: ZA; South Africa
Prior art keywords: tramadol; composition; ratio; substance; fraction
Prior art date: 1999-08-20

Application number

ZA200201403A

Other languages

English (en)

Inventor

Ellen E Codd

Kathryn E Rogers

Rebecca P Martinez

Original Assignee

Ortho Mcneil Pharm Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-08-20

Filing date

2002-02-19

Publication date

2003-07-30

2002-02-19 Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc

2003-07-30 Publication of ZA200201403B publication Critical patent/ZA200201403B/en

Links

TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 title claims description 176
TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 title claims description 175
229960004380 tramadol Drugs 0.000 title claims description 167
239000000463 material Substances 0.000 title claims description 120
239000000203 mixture Substances 0.000 title claims description 116
239000001961 anticonvulsive agent Substances 0.000 title claims description 110
238000000034 method Methods 0.000 claims description 64
208000002193 Pain Diseases 0.000 claims description 63
UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims description 56
KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 claims description 56
229960004394 topiramate Drugs 0.000 claims description 56
230000036407 pain Effects 0.000 claims description 55
239000008194 pharmaceutical composition Substances 0.000 claims description 55
239000000126 substance Substances 0.000 claims description 45
OLBWFRRUHYQABZ-MRVPVSSYSA-N carisbamate Chemical compound NC(=O)OC[C@@H](O)C1=CC=CC=C1Cl OLBWFRRUHYQABZ-MRVPVSSYSA-N 0.000 claims description 33
PPKXEPBICJTCRU-XMZRARIVSA-N (R,R)-tramadol hydrochloride Chemical compound Cl.COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 PPKXEPBICJTCRU-XMZRARIVSA-N 0.000 claims description 30
229960003107 tramadol hydrochloride Drugs 0.000 claims description 30
229960001848 lamotrigine Drugs 0.000 claims description 29
PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 claims description 29
229960002870 gabapentin Drugs 0.000 claims description 28
239000003814 drug Substances 0.000 claims description 27
CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 claims description 19
238000001356 surgical procedure Methods 0.000 claims description 18
MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 claims description 15
-1 N-oxide derivative of (1R,2R)-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)-cyclohexanol Chemical class 0.000 claims description 14
229960002036 phenytoin Drugs 0.000 claims description 14
208000012902 Nervous system disease Diseases 0.000 claims description 13
230000000926 neurological effect Effects 0.000 claims description 13
208000020016 psychiatric disease Diseases 0.000 claims description 13
241000124008 Mammalia Species 0.000 claims description 11
UWJUQVWARXYRCG-HIFRSBDPSA-N O-Desmethyltramadol Chemical compound CN(C)C[C@H]1CCCC[C@]1(O)C1=CC=CC(O)=C1 UWJUQVWARXYRCG-HIFRSBDPSA-N 0.000 claims description 11
150000003839 salts Chemical class 0.000 claims description 10
229960000604 valproic acid Drugs 0.000 claims description 10
208000004296 neuralgia Diseases 0.000 claims description 8
208000021722 neuropathic pain Diseases 0.000 claims description 8
208000028867 ischemia Diseases 0.000 claims description 7
230000004770 neurodegeneration Effects 0.000 claims description 7
230000009692 acute damage Effects 0.000 claims description 6
208000014674 injury Diseases 0.000 claims description 6
230000001404 mediated effect Effects 0.000 claims description 6
230000008733 trauma Effects 0.000 claims description 6
SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims description 5
208000000094 Chronic Pain Diseases 0.000 claims description 5
AJXPJJZHWIXJCJ-UHFFFAOYSA-N Methsuximide Chemical compound O=C1N(C)C(=O)CC1(C)C1=CC=CC=C1 AJXPJJZHWIXJCJ-UHFFFAOYSA-N 0.000 claims description 5
208000016285 Movement disease Diseases 0.000 claims description 5
150000001204 N-oxides Chemical class 0.000 claims description 5
XPFRXWCVYUEORT-UHFFFAOYSA-N Phenacemide Chemical compound NC(=O)NC(=O)CC1=CC=CC=C1 XPFRXWCVYUEORT-UHFFFAOYSA-N 0.000 claims description 5
WLWFNJKHKGIJNW-UHFFFAOYSA-N Phensuximide Chemical compound O=C1N(C)C(=O)CC1C1=CC=CC=C1 WLWFNJKHKGIJNW-UHFFFAOYSA-N 0.000 claims description 5
HMHVCUVYZFYAJI-UHFFFAOYSA-N Sultiame Chemical compound C1=CC(S(=O)(=O)N)=CC=C1N1S(=O)(=O)CCCC1 HMHVCUVYZFYAJI-UHFFFAOYSA-N 0.000 claims description 5
229960000571 acetazolamide Drugs 0.000 claims description 5
BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 claims description 5
208000005298 acute pain Diseases 0.000 claims description 5
229940049706 benzodiazepine Drugs 0.000 claims description 5
229960000623 carbamazepine Drugs 0.000 claims description 5
FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims description 5
229960001403 clobazam Drugs 0.000 claims description 5
CXOXHMZGEKVPMT-UHFFFAOYSA-N clobazam Chemical compound O=C1CC(=O)N(C)C2=CC=C(Cl)C=C2N1C1=CC=CC=C1 CXOXHMZGEKVPMT-UHFFFAOYSA-N 0.000 claims description 5
229960003120 clonazepam Drugs 0.000 claims description 5
DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 claims description 5
NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims description 5
229940064790 dilantin Drugs 0.000 claims description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
229940028937 divalproex sodium Drugs 0.000 claims description 5
229960002767 ethosuximide Drugs 0.000 claims description 5
HAPOVYFOVVWLRS-UHFFFAOYSA-N ethosuximide Chemical compound CCC1(C)CC(=O)NC1=O HAPOVYFOVVWLRS-UHFFFAOYSA-N 0.000 claims description 5
229960003533 ethotoin Drugs 0.000 claims description 5
SZQIFWWUIBRPBZ-UHFFFAOYSA-N ethotoin Chemical compound O=C1N(CC)C(=O)NC1C1=CC=CC=C1 SZQIFWWUIBRPBZ-UHFFFAOYSA-N 0.000 claims description 5
XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 claims description 5
229960001596 famotidine Drugs 0.000 claims description 5
230000004968 inflammatory condition Effects 0.000 claims description 5
229940098829 magnesium sulfate injection Drugs 0.000 claims description 5
229960000906 mephenytoin Drugs 0.000 claims description 5
GMHKMTDVRCWUDX-UHFFFAOYSA-N mephenytoin Chemical compound C=1C=CC=CC=1C1(CC)NC(=O)N(C)C1=O GMHKMTDVRCWUDX-UHFFFAOYSA-N 0.000 claims description 5
229960003729 mesuximide Drugs 0.000 claims description 5
229960003396 phenacemide Drugs 0.000 claims description 5
229960002695 phenobarbital Drugs 0.000 claims description 5
DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 claims description 5
229960004227 phensuximide Drugs 0.000 claims description 5
229960002790 phenytoin sodium Drugs 0.000 claims description 5
229960001233 pregabalin Drugs 0.000 claims description 5
AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 claims description 5
229960002393 primidone Drugs 0.000 claims description 5
DQMZLTXERSFNPB-UHFFFAOYSA-N primidone Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NCNC1=O DQMZLTXERSFNPB-UHFFFAOYSA-N 0.000 claims description 5
229960002752 progabide Drugs 0.000 claims description 5
IBALRBWGSVJPAP-HEHNFIMWSA-N progabide Chemical compound C=1C(F)=CC=C(O)C=1C(=N/CCCC(=O)N)/C1=CC=C(Cl)C=C1 IBALRBWGSVJPAP-HEHNFIMWSA-N 0.000 claims description 5
FJPYVLNWWICYDW-UHFFFAOYSA-M sodium;5,5-diphenylimidazolidin-1-ide-2,4-dione Chemical compound [Na+].O=C1[N-]C(=O)NC1(C=1C=CC=CC=1)C1=CC=CC=C1 FJPYVLNWWICYDW-UHFFFAOYSA-M 0.000 claims description 5
239000012453 solvate Substances 0.000 claims description 5
229960002573 sultiame Drugs 0.000 claims description 5
229960004453 trimethadione Drugs 0.000 claims description 5
IRYJRGCIQBGHIV-UHFFFAOYSA-N trimethadione Chemical compound CN1C(=O)OC(C)(C)C1=O IRYJRGCIQBGHIV-UHFFFAOYSA-N 0.000 claims description 5
XWLUWCNOOVRFPX-UHFFFAOYSA-N Fosphenytoin Chemical compound O=C1N(COP(O)(=O)O)C(=O)NC1(C=1C=CC=CC=1)C1=CC=CC=C1 XWLUWCNOOVRFPX-UHFFFAOYSA-N 0.000 claims description 4
FWJKNZONDWOGMI-UHFFFAOYSA-N Metharbital Chemical compound CCC1(CC)C(=O)NC(=O)N(C)C1=O FWJKNZONDWOGMI-UHFFFAOYSA-N 0.000 claims description 4
VQASKUSHBVDKGU-UHFFFAOYSA-N Paramethadione Chemical compound CCC1(C)OC(=O)N(C)C1=O VQASKUSHBVDKGU-UHFFFAOYSA-N 0.000 claims description 4
201000010099 disease Diseases 0.000 claims description 4
229960000693 fosphenytoin Drugs 0.000 claims description 4
229960002057 metharbital Drugs 0.000 claims description 4
229960003274 paramethadione Drugs 0.000 claims description 4
206010001540 Akathisia Diseases 0.000 claims description 3
208000024827 Alzheimer disease Diseases 0.000 claims description 3
208000020925 Bipolar disease Diseases 0.000 claims description 3
208000006561 Cluster Headache Diseases 0.000 claims description 3
208000032131 Diabetic Neuropathies Diseases 0.000 claims description 3
208000019695 Migraine disease Diseases 0.000 claims description 3
206010027603 Migraine headaches Diseases 0.000 claims description 3
208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 3
208000018737 Parkinson disease Diseases 0.000 claims description 3
206010036376 Postherpetic Neuralgia Diseases 0.000 claims description 3
208000001431 Psychomotor Agitation Diseases 0.000 claims description 3
208000028017 Psychotic disease Diseases 0.000 claims description 3
208000005793 Restless legs syndrome Diseases 0.000 claims description 3
206010041250 Social phobia Diseases 0.000 claims description 3
208000026137 Soft tissue injury Diseases 0.000 claims description 3
206010044565 Tremor Diseases 0.000 claims description 3
230000001154 acute effect Effects 0.000 claims description 3
230000007850 degeneration Effects 0.000 claims description 3
230000003111 delayed effect Effects 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 3
DXASQZJWWGZNSF-UHFFFAOYSA-N n,n-dimethylmethanamine;sulfur trioxide Chemical group CN(C)C.O=S(=O)=O DXASQZJWWGZNSF-UHFFFAOYSA-N 0.000 claims description 3
210000000653 nervous system Anatomy 0.000 claims description 3
230000002981 neuropathic effect Effects 0.000 claims description 3
201000008482 osteoarthritis Diseases 0.000 claims description 3
208000028173 post-traumatic stress disease Diseases 0.000 claims description 3
208000037821 progressive disease Diseases 0.000 claims description 3
238000011084 recovery Methods 0.000 claims description 3
206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
208000011580 syndromic disease Diseases 0.000 claims description 3
206010044652 trigeminal neuralgia Diseases 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 2
125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 4
ALARQZQTBTVLJV-UHFFFAOYSA-N mephobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)N(C)C1=O ALARQZQTBTVLJV-UHFFFAOYSA-N 0.000 claims 3
229960001703 methylphenobarbital Drugs 0.000 claims 3
208000001294 Nociceptive Pain Diseases 0.000 claims 2
206010043118 Tardive Dyskinesia Diseases 0.000 claims 2
208000037816 tissue injury Diseases 0.000 claims 2
TVYLLZQTGLZFBW-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol Chemical compound COC1=CC=CC(C2(O)C(CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-UHFFFAOYSA-N 0.000 claims 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
230000002195 synergetic effect Effects 0.000 description 28
229940079593 drug Drugs 0.000 description 24
230000003574 anti-allodynic effect Effects 0.000 description 16
241000700159 Rattus Species 0.000 description 15
230000000694 effects Effects 0.000 description 12
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
239000000725 suspension Substances 0.000 description 8
239000004480 active ingredient Substances 0.000 description 7
229960003965 antiepileptics Drugs 0.000 description 7
238000012360 testing method Methods 0.000 description 7
206010022998 Irritability Diseases 0.000 description 6
241000699666 Mus <mouse, genus> Species 0.000 description 6
230000000996 additive effect Effects 0.000 description 6
230000000202 analgesic effect Effects 0.000 description 6
230000001773 anti-convulsant effect Effects 0.000 description 6
230000003502 anti-nociceptive effect Effects 0.000 description 6
239000012153 distilled water Substances 0.000 description 6
210000002683 foot Anatomy 0.000 description 6
239000012458 free base Substances 0.000 description 6
239000004615 ingredient Substances 0.000 description 6
239000000014 opioid analgesic Substances 0.000 description 6
238000002360 preparation method Methods 0.000 description 6
208000004454 Hyperalgesia Diseases 0.000 description 5
239000000654 additive Substances 0.000 description 5
229940035676 analgesics Drugs 0.000 description 5
239000000730 antalgic agent Substances 0.000 description 5
239000000890 drug combination Substances 0.000 description 5
230000003993 interaction Effects 0.000 description 5
229940005483 opioid analgesics Drugs 0.000 description 5
239000000243 solution Substances 0.000 description 5
239000003826 tablet Substances 0.000 description 5
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 4
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
208000025966 Neurological disease Diseases 0.000 description 4
230000036592 analgesia Effects 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 4
231100000673 dose–response relationship Toxicity 0.000 description 4
238000010438 heat treatment Methods 0.000 description 4
OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 4
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 4
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 4
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 4
210000001032 spinal nerve Anatomy 0.000 description 4
239000003981 vehicle Substances 0.000 description 4
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
238000000692 Student's t-test Methods 0.000 description 3
206010053552 allodynia Diseases 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
239000002585 base Substances 0.000 description 3
239000002775 capsule Substances 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
239000013066 combination product Substances 0.000 description 3
229940127555 combination product Drugs 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 3
238000009472 formulation Methods 0.000 description 3
229960001680 ibuprofen Drugs 0.000 description 3
238000005259 measurement Methods 0.000 description 3
229940121367 non-opioid analgesics Drugs 0.000 description 3
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
239000003960 organic solvent Substances 0.000 description 3
239000011885 synergistic combination Substances 0.000 description 3
RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 3
HBXKSXMNNGHBEA-ZBFHGGJFSA-N 1-[(1r,2r)-2-hydroxy-2-(3-methoxyphenyl)cyclohexyl]-n,n-dimethylmethanamine oxide Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)C[N+](C)(C)[O-])=C1 HBXKSXMNNGHBEA-ZBFHGGJFSA-N 0.000 description 2
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
206010010774 Constipation Diseases 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 2
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 2
208000004756 Respiratory Insufficiency Diseases 0.000 description 2
206010038678 Respiratory depression Diseases 0.000 description 2
230000003556 anti-epileptic effect Effects 0.000 description 2
229940125681 anticonvulsant agent Drugs 0.000 description 2
239000000969 carrier Substances 0.000 description 2
229960004126 codeine Drugs 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
229960002737 fructose Drugs 0.000 description 2
238000007429 general method Methods 0.000 description 2
210000000548 hind-foot Anatomy 0.000 description 2
LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 description 2
229960000240 hydrocodone Drugs 0.000 description 2
238000005304 joining Methods 0.000 description 2
239000007788 liquid Substances 0.000 description 2
229960005181 morphine Drugs 0.000 description 2
230000003533 narcotic effect Effects 0.000 description 2
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
239000003791 organic solvent mixture Substances 0.000 description 2
229960002085 oxycodone Drugs 0.000 description 2
229960005489 paracetamol Drugs 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
230000008569 process Effects 0.000 description 2
239000000047 product Substances 0.000 description 2
239000007787 solid Substances 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 description 2
FGCFTLWVTWVAPJ-UHFFFAOYSA-N 1-(3-methoxyphenyl)cyclohexan-1-ol Chemical compound COC1=CC=CC(C2(O)CCCCC2)=C1 FGCFTLWVTWVAPJ-UHFFFAOYSA-N 0.000 description 1
IUVCFHHAEHNCFT-INIZCTEOSA-N 2-[(1s)-1-[4-amino-3-(3-fluoro-4-propan-2-yloxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-6-fluoro-3-(3-fluorophenyl)chromen-4-one Chemical compound C1=C(F)C(OC(C)C)=CC=C1C(C1=C(N)N=CN=C11)=NN1[C@@H](C)C1=C(C=2C=C(F)C=CC=2)C(=O)C2=CC(F)=CC=C2O1 IUVCFHHAEHNCFT-INIZCTEOSA-N 0.000 description 1
USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 1
235000003625 Acrocomia mexicana Nutrition 0.000 description 1
244000202285 Acrocomia mexicana Species 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
208000012661 Dyskinesia Diseases 0.000 description 1
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
206010060800 Hot flush Diseases 0.000 description 1
PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
206010061296 Motor dysfunction Diseases 0.000 description 1
102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
208000028389 Nerve injury Diseases 0.000 description 1
229940127450 Opioid Agonists Drugs 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
241000011102 Thera Species 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
239000000556 agonist Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 description 1
229960001113 butorphanol Drugs 0.000 description 1
208000015114 central nervous system disease Diseases 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
QGTYWWGEWOBMAK-UHFFFAOYSA-N chlormephos Chemical compound CCOP(=S)(OCC)SCCl QGTYWWGEWOBMAK-UHFFFAOYSA-N 0.000 description 1
239000003086 colorant Substances 0.000 description 1
229940073755 combination tramadol Drugs 0.000 description 1
238000013329 compounding Methods 0.000 description 1
239000000039 congener Substances 0.000 description 1
238000001816 cooling Methods 0.000 description 1
125000000753 cycloalkyl group Chemical group 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
229960000920 dihydrocodeine Drugs 0.000 description 1
RBOXVHNMENFORY-DNJOTXNNSA-N dihydrocodeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC RBOXVHNMENFORY-DNJOTXNNSA-N 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
238000013401 experimental design Methods 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
238000009963 fulling Methods 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
239000003979 granulating agent Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
229940090044 injection Drugs 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
230000003447 ipsilateral effect Effects 0.000 description 1
229960002725 isoflurane Drugs 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
229960001797 methadone Drugs 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
239000003612 morphinomimetic agent Substances 0.000 description 1
239000003158 myorelaxant agent Substances 0.000 description 1
229960002009 naproxen Drugs 0.000 description 1
CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
230000008764 nerve damage Effects 0.000 description 1
239000004090 neuroprotective agent Substances 0.000 description 1
229940124637 non-opioid analgesic drug Drugs 0.000 description 1
239000003921 oil Substances 0.000 description 1
239000003402 opiate agonist Substances 0.000 description 1
229940124636 opioid drug Drugs 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
239000007800 oxidant agent Substances 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
208000033808 peripheral neuropathy Diseases 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
150000002989 phenols Chemical class 0.000 description 1
RGCLLPNLLBQHPF-HJWRWDBZSA-N phosphamidon Chemical compound CCN(CC)C(=O)C(\Cl)=C(/C)OP(=O)(OC)OC RGCLLPNLLBQHPF-HJWRWDBZSA-N 0.000 description 1
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
238000010791 quenching Methods 0.000 description 1
230000000171 quenching effect Effects 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
238000010992 reflux Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
210000003497 sciatic nerve Anatomy 0.000 description 1
239000002904 solvent Substances 0.000 description 1
210000003594 spinal ganglia Anatomy 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
230000035900 sweating Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
231100000027 toxicology Toxicity 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Rheumatology (AREA)
Emergency Medicine (AREA)
Psychology (AREA)
Anesthesiology (AREA)
Hospice & Palliative Care (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

ZA200201403A 1999-08-20 2002-02-19 Composition comprising a tramadol material and an anticonvulsant drug. ZA200201403B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US15020199P	1999-08-20	1999-08-20

Publications (1)

Publication Number	Publication Date
ZA200201403B true ZA200201403B (en)	2003-07-30

Family

ID=22533492

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200201403A ZA200201403B (en)	1999-08-20	2002-02-19	Composition comprising a tramadol material and an anticonvulsant drug.

Country Status (31)

Country	Link
US (1)	US6562865B1 (tr)
EP (1)	EP1210118B1 (tr)
JP (1)	JP4977297B2 (tr)
KR (1)	KR100758609B1 (tr)
CN (1)	CN1198651C (tr)
AR (1)	AR032132A1 (tr)
AT (1)	ATE284223T1 (tr)
AU (1)	AU782759B2 (tr)
BG (1)	BG65996B1 (tr)
BR (1)	BRPI0013439B8 (tr)
CA (1)	CA2381797C (tr)
CO (1)	CO5190667A1 (tr)
CR (1)	CR6593A (tr)
CZ (1)	CZ2002524A3 (tr)
DE (1)	DE60016602T2 (tr)
EA (1)	EA006598B1 (tr)
ES (1)	ES2234651T3 (tr)
HU (1)	HUP0203198A3 (tr)
IL (2)	IL148019A0 (tr)
MX (1)	MXPA02001820A (tr)
MY (1)	MY136985A (tr)
NO (1)	NO332342B1 (tr)
NZ (1)	NZ517106A (tr)
PL (1)	PL213323B1 (tr)
PT (1)	PT1210118E (tr)
SK (1)	SK286621B6 (tr)
TR (1)	TR200201067T2 (tr)
TW (1)	TWI259769B (tr)
UA (1)	UA75868C2 (tr)
WO (1)	WO2001013904A2 (tr)
ZA (1)	ZA200201403B (tr)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU651247B2 (en)	1991-09-06	1994-07-14	Mcneilab, Inc.	Composition comprising a tramadol material and acetaminophen and its use
US7164034B2 (en)	1999-06-10	2007-01-16	Pfizer Inc.	Alpha2delta ligands for fibromyalgia and other disorders
WO2001013904A2 (en)	1999-08-20	2001-03-01	Ortho-Mcneil Pharmaceutical, Inc.	Composition comprising a tramadol material and an anticonvulsant drug
DE19940740A1 (de) *	1999-08-31	2001-03-01	Gruenenthal Gmbh	Pharmazeutische Salze
DE10049483A1 (de) *	2000-09-29	2002-05-02	Gruenenthal Gmbh	Substituierte 1-Aminobutan-3-ol-Derivate
US20030092759A1 (en) *	2001-09-24	2003-05-15	Abuzzahab Faruk S.	Anticonvulsant derivatives useful for the treatment of restless limb syndrome and periodic limb movement disorder
US7927613B2 (en)	2002-02-15	2011-04-19	University Of South Florida	Pharmaceutical co-crystal compositions
US20050025791A1 (en)	2002-06-21	2005-02-03	Julius Remenar	Pharmaceutical compositions with improved dissolution
US7790905B2 (en)	2002-02-15	2010-09-07	Mcneil-Ppc, Inc.	Pharmaceutical propylene glycol solvate compositions
US20030225002A1 (en) *	2002-02-26	2003-12-04	Livingstone Ian R.	Co-therapy for the treatment of migraine comprising anticonvulsant derivatives and anti-migraine agents
JP4906233B2 (ja)	2002-03-01	2012-03-28	ユニバーシティーオブサウスフロリダ	少なくとも１種の有効薬剤成分を含有する多構成要素固相
EP1364649A1 (en) *	2002-05-23	2003-11-26	Cilag AG	Adduct of topiramate and tramadol hydrochioride and uses thereof
ES2421516T3 (es)	2002-11-06	2013-09-03	Dana Farber Cancer Inst Inc	Composiciones para tratar el cáncer usando el inhibidor de proteasomas PS-341
PL377351A1 (pl) *	2002-12-13	2006-01-23	Cilag Ag	Preparaty o kontrolowanym uwalnianiu zawierające tramadol i topiramat
US8183290B2 (en)	2002-12-30	2012-05-22	Mcneil-Ppc, Inc.	Pharmaceutically acceptable propylene glycol solvate of naproxen
KR101043789B1 (ko) *	2003-03-31	2011-06-27	(주)에이스딕시오	디지털 신호 처리를 이용한 전력 측정기 및 그 전력 측정 방법과 그 방법을 수행하는 프로그램을 기록한 컴퓨터로 읽을 수 있는 기록매체
US20090214426A1 (en) *	2004-05-19	2009-08-27	Laura Corradini	Assay Method
MY147767A (en)	2004-06-16	2013-01-31	Janssen Pharmaceutica Nv	Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
TW200612905A (en) *	2004-06-16	2006-05-01	Janssen Pharmaceutica Nv	Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
KR20070057848A (ko) *	2004-08-24	2007-06-07	얀센 파마슈티카 엔.브이.	항경련제로 유용한 신규 벤조-융합된 헤테로아릴 설파미드유도체
EA200700871A1 (ru) *	2004-10-15	2007-10-26	Янссен Фармацевтика Н. В.	Способы нейропротекции
US20060257484A1 (en) *	2005-04-19	2006-11-16	Hwang Stephen S	Combination of tramadol and substances that comprise gabapentin
AU2006249577A1 (en) *	2005-05-20	2006-11-30	Janssen Pharmaceutica N.V.	Process for preparation of sulfamide derivatives
US20070021500A1 (en) *	2005-07-12	2007-01-25	Twyman Roy E	Methods for neuroprotection
US20070112017A1 (en) *	2005-10-31	2007-05-17	Braincells, Inc.	Gaba receptor mediated modulation of neurogenesis
MXPA05011735A (es) *	2005-11-01	2007-04-30	Leopoldo Espinosa Abdala	Composiciones farmaceuticas que comprenden combinaciones de analgesicos y anticonvulsivantes para el tratamiento del dolor agudo y cronico.
US8497298B2 (en) *	2005-12-19	2013-07-30	Janssen Pharmaceutica Nv	Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US20070155827A1 (en) *	2005-12-19	2007-07-05	Smith-Swintosky Virginia L	Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
US20070155823A1 (en) *	2005-12-19	2007-07-05	Smith-Swintosky Virginia L	Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
US8492431B2 (en) *	2005-12-19	2013-07-23	Janssen Pharmaceutica, N.V.	Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
US8716231B2 (en)	2005-12-19	2014-05-06	Janssen Pharmaceutica Nv	Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8691867B2 (en) *	2005-12-19	2014-04-08	Janssen Pharmaceutica Nv	Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8937096B2 (en)	2005-12-19	2015-01-20	Janssen Pharmaceutica Nv	Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US20070191449A1 (en) *	2006-02-15	2007-08-16	Smith-Swintosky Virginia L	Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Depression
US20070191461A1 (en) *	2006-02-15	2007-08-16	Smith-Swintosky Virginia L	Use of benzo-heteroaryl sulfamide derivatives for the treatment of migraine
US20070191474A1 (en) *	2006-02-15	2007-08-16	Smith-Swintosky Virginia L	Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine
US20070191452A1 (en) *	2006-02-15	2007-08-16	Smith-Swintosky Virginia L	Use of benzo-heteroaryl sulfamide derivatives for the treatment of pain
EP2026790A2 (en) *	2006-05-19	2009-02-25	Janssen Pharmaceutica, N.V.	Co-therapy for the treatment of epilepsy and related disorders
TW200812574A (en) *	2006-05-19	2008-03-16	Janssen Pharmaceutica Nv	Co-therapy for the treatment of epilepsy and related disorders
EA027836B1 (ru) *	2006-06-15	2017-09-29	ЮСиБи ФАРМА ГМБХ	Фармацевтическая комбинация для профилактики, облегчения и/или лечения приступов эпилепсии и ее применение
US9744137B2 (en) *	2006-08-31	2017-08-29	Supernus Pharmaceuticals, Inc.	Topiramate compositions and methods of enhancing its bioavailability
CA2667510A1 (en) *	2006-10-27	2008-06-12	Janssen Pharmaceutica N.V.	Methods for treating disruptive behavior disorders
ES2555066T3 (es)	2006-11-17	2015-12-28	Supernus Pharmaceuticals, Inc.	Formulaciones de liberación sostenida de topiramato
CN102114002B (zh) *	2006-12-04	2016-05-11	苏佩努斯制药公司	托吡酯的增强的立即释放制剂
US20090076128A1 (en) *	2007-09-15	2009-03-19	Protia Llc	Deuterium-enriched topiramate
US8263652B2 (en)	2007-10-31	2012-09-11	Sk Biopharmaceuticals Co., Ltd.	Stabilized pediatric suspension of carisbamate
US8356315B2 (en) *	2007-12-03	2013-01-15	Koncelik Jr Lawrence J	Setting television default channel
US7868043B2 (en)	2008-01-25	2011-01-11	Xenoport, Inc.	Mesophasic forms of (3S)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
CA2706575C (en)	2008-01-25	2015-07-14	Xenoport, Inc.	Enantiomerically resolving acyloxyalkyl thiocarbonates used in synthesizing acyloxyalkyl carbamate prodrugs
US7872046B2 (en) *	2008-01-25	2011-01-18	Xenoport, Inc.	Crystalline form of a (3S)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use
US20090247617A1 (en) *	2008-03-26	2009-10-01	Abdel-Magid Ahmed F	Process for the preparation of benzo-fused heteroaryl sulfamates
US20090247616A1 (en) *	2008-03-26	2009-10-01	Smith-Swintosky Virginia L	Use of benzo-fused heterocyle sulfamide derivatives for the treatment of anxiety
EP2116618A1 (en)	2008-05-09	2009-11-11	Agency for Science, Technology And Research	Diagnosis and treatment of Kawasaki disease
BRPI0915890A2 (pt)	2008-06-23	2015-11-03	Janssen Pharmaceutica Nv	forma cristalina de (2s)-(-)-n-(6-cloro-2,3-di-hidro-benzo[1,4]dioxin-2-ilmetil)-sulfamida
US20100003322A1 (en) *	2008-07-03	2010-01-07	Lai Felix S	Enteric coated hydrophobic matrix formulation
US8815939B2 (en) *	2008-07-22	2014-08-26	Janssen Pharmaceutica Nv	Substituted sulfamide derivatives
US20100190752A1 (en)	2008-09-05	2010-07-29	Gruenenthal Gmbh	Pharmaceutical Combination
KR101641519B1 (ko)	2008-09-05	2016-07-21	그뤼넨탈 게엠베하	3-（3-디메틸아미노-1-에틸-2-메틸-프로필）-페놀과 항간질제의 약제학적 병용물
US20110053914A1 (en)	2009-08-28	2011-03-03	Gruenenthal Gmbh	Pharmaceutical Combination Comprising 6-Dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol or 6-Dimethylaminomethyl-1-(3-hydroxy-phenyl)-cyclohexane-1,3-diol and an Antiepileptic
EP2383255A1 (en)	2010-04-28	2011-11-02	Lacer, S.A.	New compounds, synthesis and use thereof in the treatment of pain
EP2599487B1 (en)	2010-07-30	2015-04-01	Toray Industries, Inc.	Therapeutic agent or prophylactic agent for neuropathic pain
EP2530072A1 (en)	2011-06-03	2012-12-05	Lacer, S.A.	New compounds, synthesis and use thereof in the treatment of pain
US10702485B2 (en)	2011-07-09	2020-07-07	Syntrix Biosystems Inc.	Compositions and methods for overcoming resistance to tramadol
RU2533979C1 (ru) *	2013-03-11	2014-11-27	государственное бюджетное образовательное учреждение высшего профессионального образования "Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения Российской Федерации	Способ лечения центральных стенозирующих злокачественных опухолей трахеи и бронхов
US8652527B1 (en)	2013-03-13	2014-02-18	Upsher-Smith Laboratories, Inc	Extended-release topiramate capsules
US9101545B2 (en)	2013-03-15	2015-08-11	Upsher-Smith Laboratories, Inc.	Extended-release topiramate capsules
DE102013009114A1 (de) *	2013-05-29	2014-12-04	Franz Gerstheimer	Pharmazeutische Zusammensetzung zur Überwindung von Metabolisierungsproblemen
KR20180093086A (ko)	2016-01-06	2018-08-20	론자 리미티드	개선된 생산을 위한 단백질 분해의 억제
US11464756B1 (en)	2017-05-19	2022-10-11	Jerry Darm	Mecuna pruriens, L-DOPA and 5-HTP based dietary supplements, pharmaceutical formulations and uses thereof
WO2019183146A1 (en)	2018-03-20	2019-09-26	Abraxis Bioscience, Llc	Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin
WO2020044070A1 (es)	2018-08-30	2020-03-05	Grünenthal GmbH	Combinación farmacéutica sinérgica que comprende tramadol clorhidrato y pregabalina, y su uso para el tratamiento del dolor neuropático
JP7257091B2 (ja) *	2019-06-27	2023-04-13	沼澤敏彦	認知症の治療及び予防薬
US11977085B1 (en)	2023-09-05	2024-05-07	Elan Ehrlich	Date rape drug detection device and method of using same

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3652589A (en)	1967-07-27	1972-03-28	Gruenenthal Chemie	1-(m-substituted phenyl)-2-aminomethyl cyclohexanols
US3562589A (en) *	1968-09-09	1971-02-09	Ite Imperial Corp	Electrically resetting undervoltage trip for circuit breakers
US4513006A (en) *	1983-09-26	1985-04-23	Mcneil Lab., Inc.	Anticonvulsant sulfamate derivatives
US4587252A (en) *	1984-12-18	1986-05-06	Brighton Pharmaceutical, Inc.	Hydrocodone/ibuprofen pharmaceutical compositions and method
US4569937A (en) *	1985-02-11	1986-02-11	E. I. Du Pont De Nemours And Company	Analgesic mixture of oxycodone and ibuprofen
DE69215316T2 (de)	1991-09-06	1997-03-20	Mcneilab Inc	Zusammensetzungen, die Tramadol und irgendein Kodein, Oxykoden oder Hydrokoden enthalten, und deren Verwendung
AU651247B2 (en) *	1991-09-06	1994-07-14	Mcneilab, Inc.	Composition comprising a tramadol material and acetaminophen and its use
US5516803A (en)	1991-10-30	1996-05-14	Mcneilab, Inc.	Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug
GB9417532D0 (en)	1994-08-31	1994-10-19	Zeneca Ltd	Aromatic compounds
EE04237B1 (et)	1996-08-14	2004-02-16	G.D. Searle & Co.	4-(5-metüül-3-fenüülisoksasool-4-üül)benseensulfoonamiidi kristalliline vorm, selle kasutamine ja valmistamise meetod
JP2001500121A (ja) *	1996-08-23	2001-01-09	アルゴスファーマシューティカルコーポレーション	神経障害性の痛みを治療する組成物を含む抗けいれん剤
US5760007A (en) *	1997-07-16	1998-06-02	Ortho Pharmaceutical Corporation	Anticonvulsant derivatives useful in treating neuropathic pain
AU9021298A (en) *	1997-08-15	1999-03-08	Carolyn Ann Fairbanks	Agmatine as a treatment for neuropathic pain
EP1011658B1 (en) *	1997-09-08	2005-12-07	Warner-Lambert Company Llc	Analgesic compositions comprising anti-epileptic compounds and methods of using same
WO2001013904A2 (en)	1999-08-20	2001-03-01	Ortho-Mcneil Pharmaceutical, Inc.	Composition comprising a tramadol material and an anticonvulsant drug

2000
- 2000-08-09 WO PCT/US2000/021622 patent/WO2001013904A2/en active IP Right Grant
- 2000-08-09 CN CNB008144990A patent/CN1198651C/zh not_active Expired - Lifetime
- 2000-08-09 AU AU68958/00A patent/AU782759B2/en not_active Expired
- 2000-08-09 MX MXPA02001820A patent/MXPA02001820A/es active IP Right Grant
- 2000-08-09 IL IL14801900A patent/IL148019A0/xx unknown
- 2000-08-09 CA CA002381797A patent/CA2381797C/en not_active Expired - Fee Related
- 2000-08-09 KR KR1020027002005A patent/KR100758609B1/ko active IP Right Grant
- 2000-08-09 AT AT00957321T patent/ATE284223T1/de active
- 2000-08-09 TR TR2002/01067T patent/TR200201067T2/tr unknown
- 2000-08-09 PT PT00957321T patent/PT1210118E/pt unknown
- 2000-08-09 PL PL353266A patent/PL213323B1/pl unknown
- 2000-08-09 BR BRPI0013439-2 patent/BRPI0013439B8/pt not_active IP Right Cessation
- 2000-08-09 US US09/634,904 patent/US6562865B1/en not_active Expired - Lifetime
- 2000-08-09 HU HU0203198A patent/HUP0203198A3/hu unknown
- 2000-08-09 DE DE60016602T patent/DE60016602T2/de not_active Expired - Lifetime
- 2000-08-09 EA EA200200183A patent/EA006598B1/ru not_active IP Right Cessation
- 2000-08-09 EP EP00957321A patent/EP1210118B1/en not_active Expired - Lifetime
- 2000-08-09 JP JP2001518042A patent/JP4977297B2/ja not_active Expired - Lifetime
- 2000-08-09 CZ CZ2002524A patent/CZ2002524A3/cs unknown
- 2000-08-09 ES ES00957321T patent/ES2234651T3/es not_active Expired - Lifetime
- 2000-08-09 SK SK226-2002A patent/SK286621B6/sk not_active IP Right Cessation
- 2000-08-09 NZ NZ517106A patent/NZ517106A/en not_active IP Right Cessation
- 2000-08-18 MY MYPI20003811A patent/MY136985A/en unknown
- 2000-08-18 AR ARP000104303A patent/AR032132A1/es unknown
- 2000-08-18 CO CO00062273A patent/CO5190667A1/es active IP Right Grant
- 2000-09-08 UA UA2002021306A patent/UA75868C2/uk unknown
- 2000-09-18 TW TW089116948A patent/TWI259769B/zh not_active IP Right Cessation
2002
- 2002-02-05 IL IL148019A patent/IL148019A/en active IP Right Grant
- 2002-02-13 NO NO20020728A patent/NO332342B1/no not_active IP Right Cessation
- 2002-02-19 ZA ZA200201403A patent/ZA200201403B/en unknown
- 2002-02-19 BG BG106420A patent/BG65996B1/bg unknown
- 2002-02-20 CR CR6593A patent/CR6593A/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
SK2262002A3 (en)	2003-02-04
PT1210118E (pt)	2005-02-28
TWI259769B (en)	2006-08-11
EP1210118A2 (en)	2002-06-05
HUP0203198A2 (hu)	2003-02-28
PL213323B1 (pl)	2013-02-28
BRPI0013439A (pt)	2002-04-30
CA2381797C (en)	2008-04-15
AU782759B2 (en)	2005-08-25
IL148019A (en)	2012-03-29
NO20020728D0 (no)	2002-02-13
NZ517106A (en)	2005-04-29
CR6593A (es)	2009-01-16
AR032132A1 (es)	2003-10-29
MY136985A (en)	2008-12-31
CO5190667A1 (es)	2002-08-29
TR200201067T2 (tr)	2002-09-23
NO332342B1 (no)	2012-09-03
EA006598B1 (ru)	2006-02-24
BG65996B1 (bg)	2010-09-30
SK286621B6 (sk)	2009-02-05
BG106420A (bg)	2002-09-30
WO2001013904A3 (en)	2001-06-14
WO2001013904A2 (en)	2001-03-01
CZ2002524A3 (cs)	2002-11-13
BRPI0013439B8 (pt)	2021-07-06
ES2234651T3 (es)	2005-07-01
US6562865B1 (en)	2003-05-13
JP2003507421A (ja)	2003-02-25
DE60016602D1 (de)	2005-01-13
NO20020728L (no)	2002-04-05
JP4977297B2 (ja)	2012-07-18
KR20020025221A (ko)	2002-04-03
EP1210118B1 (en)	2004-12-08
HUP0203198A3 (en)	2005-07-28
CN1198651C (zh)	2005-04-27
IL148019A0 (en)	2002-09-12
MXPA02001820A (es)	2003-07-14
AU6895800A (en)	2001-03-19
DE60016602T2 (de)	2005-11-03
PL353266A1 (en)	2003-11-03
UA75868C2 (en)	2006-06-15
KR100758609B1 (ko)	2007-09-13
ATE284223T1 (de)	2004-12-15
CA2381797A1 (en)	2001-03-01
BRPI0013439B1 (pt)	2012-07-24
CN1379686A (zh)	2002-11-13
EA200200183A1 (ru)	2002-08-29

Publication	Publication Date	Title
EP1210118B1 (en)	2004-12-08	Composition comprising a tramadol material and an anticonvulsant drug
AU651247B2 (en)	1994-07-14	Composition comprising a tramadol material and acetaminophen and its use
DE69733081T2 (de)	2006-05-11	Antikonvulsive mitteln enthaltende zubereitung zur behandlung von neuropathischen schmerzen
KR100236666B1 (ko)	2000-03-02	트라마돌 및 코데인, 옥시코돈 또는 하이드로코돈을 함유하는 조성물 및 그의 용도
Bartolini et al.	2011	Analgesic and antineuropathic drugs acting through central cholinergic mechanisms
US8710040B2 (en)	2014-04-29	Pharmaceutical composition comprising gabapentin or an analogue thereof and an α-aminoamide and its analgesic use
US20030013689A1 (en)	2003-01-16	Method for treating pain
AU3384200A (en)	2000-09-21	Composition comprising a tramadol material and a selective cox-2 inhibitor drug
IE58314B1 (en)	1993-09-08	Pharmaceutical products providing enhanced analgasia
NO302736B1 (no)	1998-04-20	Farmasöytisk preparat omfattende tramadol og ibuprofen
EP0759750A1 (en)	1997-03-05	Compositions for treatment of chronic inflammatory diseases
KR20090018863A (ko)	2009-02-23	통증성 의학적 상태를 위한 치료제 조합
AU2002333374A1 (en)	2003-06-05	Pharmaceutical composition comprising gabapentin or an analogue thereof and an (alpha)- aminoamide and its analgesic use
MXPA05011735A (es)	2007-04-30	Composiciones farmaceuticas que comprenden combinaciones de analgesicos y anticonvulsivantes para el tratamiento del dolor agudo y cronico.
EP0371085A1 (en)	1990-06-06	Dextromethorphan potentiator for anticonvulsant composition and method
Doyle et al.	1998	Investigation of the actions and antagonist activity of some polyamine analogues in vivo